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Background: White sponge nevus (WSN) is a rare periodontal hereditary disease. To date, almost all WSN studies
have focused on case reports or mutation reports. Thus, the mechanism behind WSN is still unclear. We
investigated the pathogenesis of WSN using expression profiling.
Methods: Sequence analysis of samples from a WSN Chinese family revealed a mutation (332 T > C) in the KRT13
gene that resulted in the amino acid change Leu111Pro. The pathological pathway behind the WSN expression
profile was investigated by RNA sequencing (RNA-seq).
Results: Construction of a heatmap revealed 24 activated genes and 57 reduced genes in the WSN patients. The
ribosome structure was damaged in the WSN patients. Moreover, the translation rate was limited in the WSN
patients, whereas ubiquitin-mediated proteolysis was enhanced.
Conclusions: Our results suggest that the abnormal degradation of the KRT13 protein in WSN patients may be
associated with keratin 7 (KRT7) and an abnormal ubiquitination process.
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White sponge nevus (WSN) is a rare periodontal hereditary
disease that was first described by Hyde [1] and coined by
Cannon [2]. It is characterized by white, thickened, folded
and spongy lesions of the oral mucosa, although the esopha-
geal, laryngeal, nasal and anogenital mucosa might also be
affected [3]. Recently, KRT4 [4] and KRT13 [5] gene muta-
tions were shown be the underlying cause of WSN. WSN is
an autosomal dominant genetic disease in the oral mucosa.
Although WSN patients do not experience significant phys-
ical pain, they often complain of an altered texture of the
mucosa or changes in their physical appearance induced by
the lesions. To develop better therapeutic strategies for* Correspondence: shangfengliufudan@163.com; slzhao@tongji.edu.cn;
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creativecommons.org/publicdomain/zero/1.0/WSN, it is important to understand the consequences of the
associated genetic mutations and molecular changes. To
date, many WSN cases have been reported around the
world, including China [6–8], Italy [9–11], Japan [12, 13],
the UK [14, 15], Spain [16], Scotland [17], Iran [18], Brazil
[19], and Turkey [20]. However, the exact pathogenic mech-
anism behind WSN remains unclear. With the advent of
next-generation sequencing technologies, RNA-seq has be-
come a useful tool for defining the transcriptomes of cells.
Moreover, this technology may be useful for analyzing gene
expression at the exon level and delineating novel splicing
variants [21–25]. Early applications of RNA-seq included ex-
pression profiling of yeast [26], mouse brains, liver tissues,
skeletal muscle tissues [27], human embryonic kidneys, B
cell lines [28] and early embryos [29]. RNA-seq offers several
advantages over other expression profiling technologies, in-
cluding higher sensitivity and the ability to detect splicing
isoforms and somatic mutations [30]. To date, an RNA-seq
analysis of WSN has not been published. Therefore, we ap-
plied RNA-seq technology to analyze WSN.e distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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and mutations. However, the use of the modularity of
transcriptional networks as a principle approach to
understand this complex pathway has not been ad-
equately explored. Elucidating the molecular mecha-
nisms is a key factor for the development of successful
treatments for WSN. In this study, we investigated the
pathological pathway behind the WSN expression profile
using RNA sequencing (RNA-seq).
This study provided a new direction for investigations
into the mechanisms behind WSN, prenatal diagnosis
and clinical treatment. Furthermore, our results provide
a frame of reference and instructions for treating peri-
odontal disease and other keratin-related diseases.
Methods
Ethics approval
Oral epidermis tissues were obtained from patients who
were well informed of all of the purposes that the tissues
might be used for in this study. This study was approved
by Fudan University’s ethics committee.
Clinical report
The proband in the WSN family was a 44-year-old male
Chinese patient from Hunan province who was affected
by white asymptomatic oral plaques that were clinically
diagnosed as WSN. In this six-generation-family from
Hunan province, there were 120 members. Using pedi-
gree analysis, we determined that the genetic modes of
the disease for 28 WSN patients from this family were
autosomal dominant disorders. The incidence of WSN
was 23.3 % in this family. The major lesionsin these pa-
tients were white plaques of the tongue and the buccal
mucosa on both sides. The diagnosis of WSN was sup-
ported by the family history and the clinical and histo-
pathological findings.
Establishment of the cell lines
Oral epithelial cells from the normal subjects and the
WSN patients were cultured in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS), 100 units/ml penicillin, and 100 μg/
ml streptomycin at 37 °C in 5 % CO2.
RNA isolation and library construction
Total cellular RNA from the normal subjects and the
WSN patients was extracted using the Trizol Reagent
(Invitrogen, USA). Library construction was performed
following the Illumina manufacturer’s suggestions. The
libraries were sequenced on the Illumina Hiseq 2000
platform. Sequencing reads that contained polyA, low
quality, and adapters were pre-filtered prior to mapping.
The filtered reads were mapped on to the hg19 genome
and the mm9 genome using default parameters withBWA aligner29; reads that failed to map to the genome
were re-mapped to their respective mRNA sequences to
capture reads that spanned exons.
RNA-Seq analysis and pathogenic pathway analysis
We generated signal networks to identify and visualize
the hub genes. We expected that module genes would
have significant positive module membership values.
Functional annotation was performed with the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) Bioinformatics Resource. We focused our
bioinformatics analysis on Ingenuity Pathways Analysis
(IPA), Kyoto Encyclopedia of Genes and Genomes
(KEGG) and Gene Set Enrichment Analysis (GSEA).
RNA-seq represented an advanced method to investigate
disease pathogenesis.
Results
Clinical report and establishment of the cell line
During the oral clinical examination, the WSN patient
had white lesions located bilaterally on the lips, the lat-
eral margin of the tongue and the bilateral buccal mu-
cosa (Fig. 1a). The arrow in Fig. 1b indicates the position
of the 332 T > C mutation identifiedin this family, this
mutation predicts the amino acid change Leu111Pro. To
investigate the pathogenic mechanism behind WSN, we
collected tissues from the oral mucosa of WSN patients
and normal controls from the same family for cell cul-
ture. The cells of the two cell lines attached and showed
typical morphology for oral mucosa cells. Then, we
established a stable mesenchymal stem cell line (MSC)
from the subjects’ gum tissues and analyzed the cells by
FACS (Fig. 1c).
RNA-Seq analysis and pathogenic pathway analysis
The scatterplot in Fig. 2a depicts the number of acti-
vated (red) and reduced (green) genes in the normal
subjects compared to the WSN subjects. The heatmap
demonstrated the presence of 24 activated genes and 57
reduced genes in the WSN patient relative to the control
(Fig. 2b). Using the IPA software package, we identified
19 significant bio-function terms and 10 significant ca-
nonical pathways through KEGG analysis (Fig. 3a and b)
(Additional files 1 and 2).The strongest enriched gene
ontology terms found in the GSEA/GO analysis indi-
cated that genes involved in the structural constituents
of ribosomes are expressed at reduced levels in WSN pa-
tients; this finding is in agreement with the observation
that the structure of the ribosome is damaged in WSN
patients (Fig. 4a). The snapshot of the KEGG enrich-
ment pathways showed that protein degradation levels
and ubiquitin-mediated proteolysis were enhanced in
the WSN patients (Fig. 4b). Next, we chose the top 20
upregulated classes between the normal subjects and the
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Fig. 1 Mutation analysis and establishment of cell lines. a: White spongy oral plaques in the buccal mucosa of the normal subjects and the WSN
patients; b: Partial DNA sequences of exon 1A of the KRT13 gene from a Chinese family. The arrow indicates the position of the mutation
332 T > C. This mutation predicts the amino acid change L111P in the KRT13 polypeptide from the WSN patient; c: FACS analysis of human
mesenchymal stem cells (MSC) isolated from gum tissues
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tween the size, enrichment score (ES) and NES (Tables 1
and 2) between the 2 groups. The WSN enrichment area
was mainly focused on monooxygenase activity, the JAK
Stat cascade, and extracellular regions. In contrast,
enrichment areas from the normal patient included the
detection of stimuli and G-protein signaling.
We used signaling networks to identify and visualize
the hub genes. We expected the module genes to have
significant positive module membership values. Then,we constructed a network using published data sets and
generated an independent list of hub genes.
We compared the expression levels of different KRT
proteins from the normal subjects and the WSN pa-
tients. The KRT7 expression level was lower in the WSN
patients; however, there was almost no change in the
KRT13 levels (Fig. 5a).The constructed pathway was in
agreement with the module visualization of network
connections and associated functions. The function of
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Fig. 2 RNA-seq analysis. a: The distribution of differentially expressed genes between the normal subjects and the WSN patients; b: Scatterplot
showing the number of activated (red) and reduced (green) genes in the normal subjects compared to the WSN patients; c: Heatmap showing
the relative expression of activated genes in the WSN patients (n = 24)
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levels between the normal subjects and the WSN sam-
ples (Fig. 5c). Thus, the abnormal degradation of the
KRT13 protein in the WSN patients may be associated
with an abnormal ubiquitination process.
Discussion
With the development of sequencing technology, there
are two important bioinformatic gene expression profil-
ing methods: Microarray and RNA-Seq. In oral research,
microarrays have diverse applications in oral cancers,including early diagnosis of the transformation of pre-
malignant lesions, identification of malignancy in tissue
biopsies, drug discovery, identification of biomarkers,
and subclassification of histologically identified tumors
[31]. In premalignant lesions, such as leukoplakias and
erythroplakias, microarrays have been used to identify
genes that could serve as biomarkers for dysplastic le-
sions with the potential to progress to cancer [32]. For
clinical applications, microarrays have been used for a
longer period of time and will probably have regulatory













Fig. 3 Functional analysis and pathway analysis. a: Functional annotation of differentially expressed genes; b: Pathway analysis
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tinely than microarray, but right now the techniques can
be complementary to each other. Microarrays will not
become obsolete but might be relegated to only a few
uses. RNA-Seq clearly has a bright future in bioinfor-
matic data collection [33].
WSN is a rare oral hereditary disease. Gene expression
profiling of WSN patientshas not elucidated the mecha-
nisms behind this disease. In this study, we analyzed the
expression differences at the gene level between normal
subjects and WSN patients and found 81 differentially
expressed genes. These genes was divided into 8 cat-
egories according to their gene function and 10 canon-
ical pathways, which provided important clues forunderstanding the molecular mechanisms behind
WSN pathogenesis.
In summary, we demonstrated that the use of RNA-
seq markedly improved the transcriptome quantification
associated with WSN. We expect that RNA-seq will also
be useful for quantitatively delineating the structures,
isoforms, and specific expression patterns of both coding
genes and non-coding regulatory RNAs. Furthermore,
RNA-seq analysis has the advantage of providing quanti-
tative results, which is in contrastto exome or genomic
sequencing.
To the best of our knowledge, WSN is an autosomal
dominant genetic disease. Therefore, there is no appro-
priate animal model or no effective therapeutic drugs
AB
Fig. 4 Gene Ontology and KEGG Enrichment analysis. a: The strongest enriched Gene Ontology terms in the GSEA/GO analysis; b: The snapshot
of KEGG enrichment
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hibit significant physical pain, they often complain of an
altered texture of the mucosa or changes to their phys-
ical appearance induced by the lesions. To develop bet-
ter therapeutic strategies for WSN, it is important to
understand the consequences of the associated genetic
mutations and molecular changes. Therefore, we investi-
gated the pathogenesis and signaling pathways involved
in WSN using RNA-seq. Our results suggested that the
KRT13 mutation may be associate with KRT7 and UBC.
UBC is a protein-coding gene that encodes a ubiquitin
protein that exists either covalently attached to another
protein or free (unanchored). Our previous study found
that the abnormal degradation of the KRT13 protein in
WSN patients contributed to an abnormal ubiquitina-
tion process [6]. Therefore, a key target for the treat-
ment of WSN is to prevent the degradation of the
KRT13 protein.
Our study utilized a next generation sequencing plat-
form to comprehensively characterize the KRT13-related
WSN transcriptome for the first time. It provided thebasis for an understanding of the molecular mechanisms
behind WSN pathogenesis at a system-wide level. Future
research based on our findings may speed up the discov-
ery of novel biomarkers and drug targets that can be
used to improve the diagnosis and therapy of WSN. The
results of our RNA-Seq analysis suggested that the
abnormal degradation of the KRT13 protein in WSN
patients may be associated with keratin 7 (KRT7) and an
abnormal ubiquitination process. The structure of the
ribosome was found to be damaged in WSN patients.
Moreover, the translation rate was reduced in WSN pa-
tients, whereas ubiquitin-mediated proteolysis was en-
hanced. Therefore, the development of a valuable drug
to reduce the degradation of KRT13is crucial for WSN
patients. We are optimistic that the problem will be
solved with future studies on WSN. We also expect the
development of RNA-Seq to enable applications involved
in determining the structural dynamics of the transcrip-
tome and the pathogenic mechanism of disease.
Although WSN patients had no physical pain signifi-
cantly, but they often complained of an altered texture
Table 1 GSEA analysis of a normal subject
Number Upregulated on normal Size ES NES
1 DETECTION_OF_STIMULUS 27 −0.6574245 −1.8061078
2 G_PROTEIN_SIGNALING_COUPLED_TO_IP3_SECOND_MESSENGERPHOSPHOLIPASE_C_ACTIVATING 24 −0.6308761 −1.6817592
3 PHOSPHOINOSITIDE_MEDIATED_SIGNALING 27 −0.60555935 −1.6654842
4 POTASSIUM_CHANNEL_ACTIVITY 32 −0.56262994 −1.5977739
5 HYDROLASE_ACTIVITY_ACTING_ON_CARBON_NITROGEN_NOT_PEPTIDEBONDS 25 −0.5852488 −1.5726966
6 POTASSIUM_ION_TRANSPORT 36 −0.53710914 −1.5694768
7 CATION_CHANNEL_ACTIVITY 82 −0.46867418 −1.5630565
8 SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY 106 −0.44555083 −1.5522181
9 ANION_TRANSPORT 16 −0.6484232 −1.5312126
10 GATED_CHANNEL_ACTIVITY 86 −0.44908124 −1.5255814
11 HORMONE_METABOLIC_PROCESS 18 −0.61389524 −1.5086162
12 SULFOTRANSFERASE_ACTIVITY 18 −0.60654145 −1.4967437
13 ION_CHANNEL_ACTIVITY 101 −0.43095177 −1.4898388
14 HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_BINDING 20 −0.5910758 −1.4891092
15 CELL_CYCLE_PROCESS 107 −0.41814068 −1.4650342
16 VOLTAGE_GATED_CATION_CHANNEL_ACTIVITY 44 −0.48482108 −1.463665
17 AXONOGENESIS 26 −0.54742056 −1.4614419
18 HEART_DEVELOPMENT 19 −0.5847264 −1.4440396
19 LIGAND_GATED_CHANNEL_ACTIVITY 30 −0.51191664 −1.4319984
20 NEUROTRANSMITTER_RECEPTOR_ACTIVITY 32 −0.500388 −1.4252495
Table 2 GSEA analysis of a WSN patient
Number Upregulated on WSN Size ES NES
1 MONOOXYGENASE_ACTIVITY 17 0.76 1.85
2 JAK_STAT_CASCADE 21 0.69 1.8
3 EXTRACELLULAR_REGION_PART 216 0.47 1.8
4 SUGAR_BINDING 22 0.69 1.79
5 CARBOHYDRATE_BINDING 45 0.59 1.79
6 LIPID_RAFT 15 0.73 1.75
7 PROTEASE_INHIBITOR_ACTIVITY 21 0.66 1.72
8 POSITIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS 17 0.67 1.67
9 NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 21 0.66 1.67
10 PROTEINACEOUS_EXTRACELLULAR_MATRIX 65 0.51 1.67
11 RAS_GTPASE_BINDING 17 0.68 1.66
12 EXTRACELLULAR_REGION 281 0.43 1.66
13 STRUCTURAL_CONSTITUENT_OF_MUSCLE 15 0.7 1.66
14 EXTRACELLULAR_MATRIX 66 0.51 1.65
15 COAGULATION 31 0.58 1.65
16 POSITIVE_REGULATION_OF_TRANSLATION 22 0.62 1.65
17 VIRAL_REPRODUCTIVE_PROCESS 22 0.62 1.64
18 EXTRACELLULAR_SPACE 155 0.44 1.63
19 BLOOD_COAGULATION 30 0.58 1.62
20 PROTEIN_TYROSINE_PHOSPHATASE_ACTIVITY 29 0.59 1.62





























Fig. 5 Pathogenic mechanism analysis. a: The KRT expression levels between the normal subjects and the WSN patients; b: Module visualization
of network connections and associated functions. Bioinformatics analysis of target genes and network analysis of these genes using the String 8.3
software indicated the central involvement of KRT 13 signaling; c: The UBC expression levels between the normal subjects and the WSN patients
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Many WSN patients made therapy treatments medica-
tion with nystatin, antihistamines, vitamins and mouth
rinses. Azithromycin, tetracycline [5], chlorhexidine [34],
Victoria A acid [35] and penicillin had succeed in the
clinical progress. However, there is no standard treat-
ment protocol for WSN till now. We applied RNA-seq
technology to explor the WSN mechanism. The Human
induced pluripotent stem cells (iPSCs) represent an ex-
cellent tool for many clinical trials [36]. The RNA-seq
technology and induced pluripotent stem cells (iPSCs)
technology may be a point way to the treatment of the
rare disease. Meanwhile the WSN patient should per-
form a careful oral hygiene to reduce infection in the
oral cavity. To lead to the proper diagnosis and treat-
ment of this rare disease, it is great importance of col-
laboration between anamnesis, clinical examination andpathologic findings. With the further research of WSN,
there is optimism that the problem will be solved in the
next decade years.
Conclusions
The genetic disease WSN occurs infrequently. Experts
have struggled to grasp factors contributing to its clinical
symptoms, gene mutations and treatment; however, the
mechanism behind the disease is still unclear. Here, we
report the pathogenic mechanism of WSN. Our results
suggest that the abnormal degradation of the KRT13
protein in WSN patients may be associated with KRT7
and an abnormal ubiquitination process. This finding
may contribute to the development of a molecular ther-
apy for WSN. Gene-based diagnosis and therapy for
WSN patients may become available in the near future
and may provide references and instructions for treating
Cai et al. Orphanet Journal of Rare Diseases  (2015) 10:72 Page 9 of 10other keratin-associated diseases. This finding will hope-
fully improve the levels of prenatal diagnoses and treat-
ment of rare diseases.
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